Its inhibition synergizes with conventional chemotherapy (e.g., resensitizing FLT3-ITD+ AML to cytarabine [10]) and emerging immunotherapies (e.g., enhancing CAR-T infiltration in glioblastoma by normalizing vasculature [13]). This evidence concerns the gene FLT3 and acute myeloid leukemia.